Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

June 5, 2024

Study Completion Date

June 5, 2024

Conditions

Psoriatic Arthritis

Interventions

DRUG

SHR-1314 injection

DRUG

placebo

Trial Locations (1)

Huashan Hospital of the Shanghai FuDan University, Shanghai

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT05055934 - Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis | Biotech Hunter | Biotech Hunter